258 related articles for article (PubMed ID: 23390179)
21. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
22. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.
Wallin A; Göthlin M; Gustavsson M; Zetterberg H; Eckerström C; Blennow K; Edman A; Lind K; Nordlund A; Rolstad S
Dement Geriatr Cogn Disord; 2011; 32(3):193-7. PubMed ID: 22057225
[TBL] [Abstract][Full Text] [Related]
23. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
[TBL] [Abstract][Full Text] [Related]
24. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
25. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
Lorenzi M; Donohue M; Paternicò D; Scarpazza C; Ostrowitzki S; Blin O; Irving E; Frisoni GB;
Neurobiol Aging; 2010 Aug; 31(8):1443-51, 1451.e1. PubMed ID: 20541287
[TBL] [Abstract][Full Text] [Related]
26. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers.
Vercruysse O; Paquet C; Gabelle A; Delbeuck X; Blanc F; Wallon D; Dumurgier J; Magnin E; Martinaud O; Jung B; Bousiges O; Lehmann S; Delaby C; Quillard-Murain M; Peoc H K; Laplanche JL; Bouaziz-Amar E; Hannequin D; Sablonniere B; Buee L; Hugon J; Schraen S; Pasquier F; Bombois S; For The E-Plm Group
Curr Alzheimer Res; 2018; 15(7):691-700. PubMed ID: 29318973
[TBL] [Abstract][Full Text] [Related]
27. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
Blennow K; Zetterberg H
Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
[TBL] [Abstract][Full Text] [Related]
28. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
[TBL] [Abstract][Full Text] [Related]
29. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
30. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
[TBL] [Abstract][Full Text] [Related]
31. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
[TBL] [Abstract][Full Text] [Related]
32. Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.
Kester MI; Verwey NA; van Elk EJ; Blankenstein MA; Scheltens P; van der Flier WM
Neurobiol Aging; 2011 Aug; 32(8):1372-8. PubMed ID: 19748159
[TBL] [Abstract][Full Text] [Related]
33. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.
Altomare D; Ferrari C; Caroli A; Galluzzi S; Prestia A; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo ILH; Grimmer T; Redolfi A; Nordberg A; Scheltens P; Drzezga A; Frisoni GB;
J Neurol; 2019 Oct; 266(10):2535-2545. PubMed ID: 31267207
[TBL] [Abstract][Full Text] [Related]
35. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment.
Clerx L; van Rossum IA; Burns L; Knol DL; Scheltens P; Verhey F; Aalten P; Lapuerta P; van de Pol L; van Schijndel R; de Jong R; Barkhof F; Wolz R; Rueckert D; Bocchetta M; Tsolaki M; Nobili F; Wahlund LO; Minthon L; Frölich L; Hampel H; Soininen H; Visser PJ
Neurobiol Aging; 2013 Aug; 34(8):2003-13. PubMed ID: 23540941
[TBL] [Abstract][Full Text] [Related]
36. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment.
Mattsson N; Portelius E; Rolstad S; Gustavsson M; Andreasson U; Stridsberg M; Wallin A; Blennow K; Zetterberg H
J Alzheimers Dis; 2012; 30(4):767-78. PubMed ID: 22475796
[TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints.
van Harten AC; Visser PJ; Pijnenburg YA; Teunissen CE; Blankenstein MA; Scheltens P; van der Flier WM
Alzheimers Dement; 2013 Sep; 9(5):481-7. PubMed ID: 23232269
[TBL] [Abstract][Full Text] [Related]
39. CSF p-tau/Aβ
Santangelo R; Masserini F; Agosta F; Sala A; Caminiti SP; Cecchetti G; Caso F; Martinelli V; Pinto P; Passerini G; Perani D; Magnani G; Filippi M
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3152-3164. PubMed ID: 32415550
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
